Adipotide (FTPP) Chemistry: Inside a CKGGRAKDC Homing Peptidomimetic

Most peptides do one thing. Adipotide does two, and it keeps them in a single chain. One half is a molecular address — a sequence that recognizes a specific kind of blood vessel. The other half is a self-destruct signal that only wakes up once it's inside a cell. Bolt the two together and the whole point of the molecule becomes delivery: send a cell-killing payload to one tissue and nowhere else. This article walks through the Adipotide FTPP peptide structure residue by residue — the homing motif, the ring that holds it in shape, and the mirror-image effector — as a case study in how targeting chemistry gets designed. For research use only: everything below describes cell-culture and animal research, not human use.

Anatomy of the Sequence: Two Machines in One Chain

Written out, Adipotide is CKGGRAKDC-GG-D(KLAKLAK)2. Dense-looking, yes — but it breaks cleanly into three parts, and once you can see the seams the rest of the molecule falls into place.

The first block, CKGGRAKDC, is the homing motif — the address. It can't harm a cell on its own; its entire job is to recognize and stick to a particular target. The last block, D(KLAKLAK)2, is the effector — the payload that does the actual work once the molecule arrives. Between them sits GG, a two-glycine linker. Glycine is the smallest amino acid and the most flexible, so a pair of them behaves like a short hinge, letting the two working ends move independently instead of crowding each other.

That targeting-domain-plus-effector-domain arrangement is why chemists call Adipotide a chimeric, or conjugate, molecule. If you're comfortable reading a peptide sequence residue by residue, you can almost see the design intent in the letters: a recognition end, a hinge, and a business end. In the literature the compound also goes by prohibitin-targeting peptide 1, or TP01, and it carries the CAS registry number 859216-15-2 (reference).

The CKGGRAKDC Homing Motif and Its Disulfide Ring

Here's the practical question this section answers: how does a nine-letter sequence know where to go, and how does it hold its shape long enough to matter?

The two cysteines close a loop

Look at the ends of CKGGRAKDC — it opens and closes with a cysteine (the letter C). Cysteine side chains can bond to each other through their sulfur atoms, forming a disulfide bond. When the first and last residues link that way, the linear peptide is pulled into a closed loop. What was a floppy string becomes a constrained ring.

That constraint isn't cosmetic. A cyclized peptide can only fold into a narrow set of shapes, and that rigidity sharpens both how selectively it binds its target and how well it survives in a biological environment. It's the same structural idea behind other cyclized peptide structures, and a clean example of how a constrained ring shapes a peptide — flexibility traded away for specificity.

What "homing" actually means

The CKGGRAKDC homing peptide wasn't designed at a drawing board. Researchers found it using phage display, a screening method that sifts through enormous libraries of peptide sequences to see which ones stick to a chosen tissue. The winner homes to the lining of blood vessels feeding one particular tissue — a target we come back to below. For the chemistry, the point is simple: this block is an address, not a weapon. On its own, the control peptide CKGGRAKDC shows no cell-killing activity at all (study reference).

The D(KLAKLAK)2 Effector and Why D-Amino Acids Matter

If the homing motif is the address, D(KLAKLAK)2 is the sealed package. The notation is shorthand for the sequence KLAKLAK repeated twice, and the leading lowercase d is the detail that matters most.

Start with the sequence itself. KLAKLAK alternates between charged lysine (K) residues and greasy, water-avoiding leucine (L) and alanine (A) residues. That regular alternation makes the peptide amphipathic — one face electrically charged, the other oily. Amphipathic peptides of this kind are drawn to membranes. In research models, once the effector is carried inside a cell it disrupts the membranes of mitochondria — the cell's power plants — and that damage sets off apoptosis, the cell's orderly self-dismantling program. Outside a cell it's essentially inert. The mischief only happens on the inside, which is exactly why the homing motif's delivery job is so central.

Then there's the mirror-image trick. Natural amino acids come in a "left-handed" (L) form, and the enzymes that chew up peptides are built to recognize that form. The D(KLAKLAK)2 proapoptotic peptide is built instead from D-amino acids, the right-handed mirror images. Protease enzymes struggle to grip them, so the effector lasts far longer before it's broken down. Using the mirror-image form for durability is a recurring theme in peptide engineering; you can see the same logic pushed further in D-amino acid peptide designs that flip an entire sequence. This combination — a shaped, protease-resistant molecule assembled for one specific job — is what lifts Adipotide from an ordinary peptide to a peptidomimetic (review reference).

Prohibitin as the Vascular Address

Why does the target matter so much? Because the effector can't tell a fat cell from a heart cell — it damages whatever membrane it reaches. The entire safety concept of the molecule rests on the homing motif dropping that payload in one place and not others.

That place is defined by a protein called prohibitin. In the founding work, published in Nature Medicine in 2004, the CKGGRAKDC sequence was shown to bind cell-surface prohibitin — a protein that turns out to be unusually concentrated on the endothelial cells lining the blood vessels of white adipose tissue in the research animals studied (Nature Medicine, 2004). Prohibitin, in effect, acts as a molecular postal code for fat-tissue vasculature. Later analyses of the receptor complex also implicated annexin A2 (ANXA2) and other partner proteins, but prohibitin is the anchor the homing motif recognizes.

This is what makes the prohibitin adipose vasculature connection the linchpin of the whole design. The compound never has to distinguish fat cells directly. It targets the plumbing — the vessels that supply a fat depot — and lets the downstream biology follow. Because prohibitin also sits on the blood vessels of human white fat, the original authors framed the finding as a possible template for tissue-selective research tools, while being careful not to overstate it (supporting study).

A Modular Targeting Ligand

One of the most useful things about the CKGGRAKDC block is that it doesn't care what you attach to it. It's a general-purpose delivery handle for adipose-vessel endothelium, and D(KLAKLAK)2 is only one of the payloads researchers have hung off it.

In separate work, the same homing motif was paired with cytochrome c — another molecule that triggers apoptosis — and delivered through a nanoparticle carrier rather than as a direct peptide fusion (nanoparticle study). Comparative studies have set the direct-conjugate approach that Adipotide represents against nanoparticle-based delivery of a pro-death cargo to the same prohibitin-expressing vessels (comparative study). Read it that way and Adipotide becomes one instance of a broader peptidomimetic drug conjugate strategy: keep the address, swap the payload. That modularity is a big part of why the CKGGRAKDC motif keeps resurfacing in the literature long after any single compound built on it.

What Research Models Showed

It's worth being precise about what has actually been observed, and where. In a published study using mice with diet-induced obesity, animals given the peptide over roughly four weeks ended up with body weights that were no longer statistically different from lean, low-fat-diet control mice — in other words, the diet-induced obesity was largely reversed in that model (PMC study).

The mechanism behind that change was itself informative. The body-weight reduction tracked mainly with a decline in how much the animals ate, not any rise in energy expenditure, and conditioned-taste-aversion testing argued against the animals simply feeling ill. Follow-up research reported effects in non-human primate models too, published in Science Translational Medicine in 2011. The published development program was later reported as discontinued as of 2019 (reference). None of these observations describe human outcomes, and research-grade Adipotide is not equivalent to — and has never been — an approved medicine.

Frequently Asked Questions

What is the full amino acid sequence of Adipotide?

In the research literature Adipotide is written CKGGRAKDC-GG-D(KLAKLAK)2. The first block (CKGGRAKDC) is the homing motif that finds its target, a two-glycine linker (GG) sits in the middle, and D(KLAKLAK)2 is the effector segment built from D-amino acids. It is often called prohibitin-targeting peptide 1 (TP01) and carries CAS number 859216-15-2.

What does the CKGGRAKDC part of the molecule do?

CKGGRAKDC is a homing, or targeting, sequence. It was identified by phage display and binds cell-surface prohibitin, a protein enriched on the blood-vessel lining of white adipose tissue in research models. On its own it carries no cell-killing activity — it simply acts as a molecular address that concentrates the attached effector at a specific tissue's vasculature.

Why is Adipotide called a peptidomimetic rather than just a peptide?

It borrows two chemistry tricks that ordinary peptides don't. The homing block is closed into a ring by a disulfide bond between its two cysteines, and the effector block is built from D-amino acids — the mirror-image form that natural enzymes struggle to cut. Both features are deliberate engineering to improve stability and specificity, which is what earns the "mimetic" label.

Is research-grade Adipotide the same as an approved obesity drug?

No. Adipotide is an experimental compound studied only in cell-culture and animal models; its published development program was reported discontinued as of 2019, and it has never been an FDA-approved product. Research-grade material sold for laboratory use is not a medicine and is not equivalent to any approved pharmaceutical.

Putting It All Together

Adipotide is a tidy lesson in reading chemistry as intent. A disulfide-cyclized CKGGRAKDC ring supplies the address, a two-glycine hinge keeps the ends out of each other's way, and a D-amino-acid D(KLAKLAK)2 block supplies a payload that stays quiet until it's delivered inside a cell. What keeps researchers coming back isn't any single result — it's the design pattern itself: a modular homing motif you can point at a tissue and load with a payload of your choosing. To dig into the individual chemistry ideas, the linked pieces on cyclized peptides, rigid-versus-floppy structure, and D-amino-acid designs are good next stops. As always, the material described here is a subject of laboratory research only.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.